MGNX (MacroGenics Corp) Return on Gross Profit

Gross profit margin correlates with the implementation of the DART platform for creating bispecific antibodies against tumors. Research continuity is ensured by strict control over the transportation of active components. Rising Margenza sales and clinical trial successes are driving an asset revaluation, while 78.90 determines the latest production efficiency metric for MacroGenics, Inc. (MGNX) on the chart.
Financial and market metric breakdowns for MacroGenics Inc (MGNX)

MacroGenics, Inc. maintains high production efficiency protected by Dual-Affinity patents, which enables the minimization of costs when creating complex antibodies. This metric is calculated as the difference between revenue and cost of goods sold, expressed as a percentage, reflecting the business's ability to generate profit before accounting for operating expenses. An analysis of the consolidated gross margin allows for an assessment of the company's resilience to inflation and its competitive advantage over small startups.